Amylyx Pharmaceuticals (AMLX) Common Equity (2021 - 2026)
Amylyx Pharmaceuticals' Common Equity was $239.17 million in Q2 2026, up 42.5% from $167.88 million a year earlier but down 12.4% from the prior quarter.
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) Common Equity (2021 - 2026) Analysis & Trends
At the end of FY2025, Common Equity at Amylyx Pharmaceuticals came in at $305.26 million, up 85.3% from FY2024.
- In earlier years, Common Equity was $164.77 million in FY2024 (-62.0%), $433.43 million in FY2023 (+27.3%), $340.61 million in FY2022 and -$151.17 million in FY2021.
- Quarterly Common Equity has moved between -$151.17 million (Q4 2021) and $433.43 million (Q4 2023) over five years.
- Compared with a year earlier, Common Equity has increased for four straight quarters, with growth averaging 5.5% over the last eight quarters.
- The best year-over-year quarter for Common Equity over five years was Q3 2023 (growth of 190.5%); the worst was Q4 2024 (a decline of 62.0%).
- Per Business Quant data, AMLX's Common Equity in the three quarters before Q2 2026 was $273.16 million (Q1 2026), $305.26 million (Q4 2025) and $332 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Amylyx Pharmaceuticals | 3.32 Bn | 3.32 Bn | - | 239.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 239.17 Mn |
| Mar 31, 2026 | 273.16 Mn |
| Dec 31, 2025 | 305.26 Mn |
| Sep 30, 2025 | 332.00 Mn |
| Jun 30, 2025 | 167.88 Mn |
| Mar 31, 2025 | 201.42 Mn |
| Dec 31, 2024 | 164.77 Mn |
| Sep 30, 2024 | 196.20 Mn |
| Jun 30, 2024 | 261.31 Mn |
| Mar 31, 2024 | 324.44 Mn |
| Dec 31, 2023 | 433.43 Mn |
| Sep 30, 2023 | 418.40 Mn |
| Jun 30, 2023 | 386.37 Mn |
| Mar 31, 2023 | 352.65 Mn |
| Dec 31, 2022 | 340.61 Mn |
| Sep 30, 2022 | 144.03 Mn |
| Jun 30, 2022 | 192.79 Mn |
| Mar 31, 2022 | 240.95 Mn |
| Dec 31, 2021 | -151.17 Mn |
| Sep 30, 2021 | -124.07 Mn |
API Access
Amylyx Pharmaceuticals Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=AMLX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "AMLX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=AMLX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();